On August 6, 10x Genomics, Inc. fell 5.04% in regular trading, trading at $45.175/share with turnover of $31.53 million. The decline came amid broad selling pressure across the Life Sciences Tools & Services sector, with peer Illumina notably declining 5.67% on the same day.

The selloff occurred ahead of the company's Q2 earnings report scheduled for release after market close. Market consensus expected quarterly revenue of approximately $147 million, representing 5.28% year-over-year growth, with adjusted EPS of -$0.24, a 34.45% improvement from the prior year. The company had previously beaten Q1 estimates with EPS of -$0.10 versus the -$0.30 consensus and revenue of $150.8 million above the $146.4 million estimate.

Among sector peers, Thermo Fisher Scientific fell 0.51%, Danaher declined 0.97%, IQVIA dropped 2.79%, and Waters fell 1.39%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)